This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Miljic, P Articles by Colovic, M Search for Related Content PubMed PubMed Citation Articles by Miljic, P Articles by Colovic, M Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Antiribosomal-P protein antibodies in a patient with systemic lupus erythematosus and non-Hodgkin’s lymphoma: more than coincidental finding?

Institute of Haematology, Clinical Centre of Serbia, Belgrade, Serbia pedra{at}beotel.yu

B Bonaci-Nikolic

Institute of Allergy and Clinical Immunology, Clinical Centre of Serbia, Belgrade, Serbia

N Colovic

Institute of Haematology, Clinical Centre of Serbia, Belgrade, Serbia

T Terzic

Institute of Haematology, Clinical Centre of Serbia, Belgrade, Serbia

M Colovic

Institute of Haematology, Clinical Centre of Serbia, Belgrade, Serbia

Patients with systemic lupus erythematosus (SLE) are at an increased risk of lymphomas, but mechanisms underlying this association are obscure. Recently, it has been shown that antiribosomal-P protein (anti-P) antibodies cross-react with phospholipids and enhance the production of cytokines which may influence lymphomagenesis. We report a 46-year-old woman who suffered high grade diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) 28 months after the diagnosis of SLE. Development of lymphoma was associated with occurrence of serum monoclonal IgM, and pronounced prolongation of phospholipid-dependent clotting tests. Anti-P IgG antibodies were highly positive both on HEp-2 cells and in ELISA test. Anticardiolipin, anti-β2 glycoprotein I, and antiprothrombin IgM antibodies have also been found in high concentrations. Complete remission of DLBCL and SLE, with normalisation of clotting tests, and disappearance of M component was achieved with administration of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. The progression of SLE to DLBCL associated with presence of anti-P antibodies has not been previously reported. This association may not be coincidental, but further investigations are required to confirm this hypothesis.

Key Words: antiribosomal-P protein antibodies • non-Hodgkin’s lymphoma • rituximab • systemic lupus erythematosus

Lupus, Vol. 18, No. 1, 81-85 (2009)
DOI: 10.1177/0961203308093549


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?